These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9741829)

  • 1. Effect of repaglinide on insulin secretion in islets from rats infused for two days with a hypertonic solution of D-glucose.
    Louchami K; Ladrière L; Jijakli H; Malaisse WJ
    Endocrine; 1998 Jun; 8(3):247-50. PubMed ID: 9741829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of repaglinide upon nutrient metabolism, biosynthetic activity, cationic fluxes and insulin release in rat pancreatic islets.
    Louchami K; Jijakli H; Sener A; Malaisse WJ
    Res Commun Mol Pathol Pharmacol; 1998 Feb; 99(2):155-68. PubMed ID: 9583090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide.
    Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
    Eur J Pharmacol; 1998 May; 348(2-3):265-70. PubMed ID: 9652342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of insulin and somatostatin release by two meglitinide analogs.
    Leclercq-Meyer V; Ladrière L; Fuhlendorff J; Malaisse WJ
    Endocrine; 1997 Dec; 7(3):311-7. PubMed ID: 9657067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of a new class of insulin secretagogues.
    Malaisse WJ
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S140-3. PubMed ID: 10522840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency.
    Bakkali-Nadi A; Malaisse-Lagae F; Malaisse WJ
    Diabetes Res; 1994; 27(2):81-7. PubMed ID: 7671557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
    Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
    Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation between the potency and reversibility of the insulinotropic action of two meglitinide analogues.
    Jijakli H; Ulusoy S; Malaisse WJ
    Pharmacol Res; 1996; 34(3-4):105-8. PubMed ID: 9051699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
    Hu S; Wang S; Dunning BE
    Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets.
    Viñambres C; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
    Pharmacol Res; 1996; 34(1-2):83-5. PubMed ID: 8981561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the methyl esters of pyruvate, succinate and glutamate on the secretory response to meglitinide analogues in rat pancreatic islets.
    Bakkali Nadi A; Zhang TM; Malaisse WJ
    Pharmacol Res; 1996 Mar; 33(3):191-4. PubMed ID: 8880890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulinotropic action of meglitinide analogues: modulation by an activator of ATP-sensitive K+ channels and high extracellular K+ concentrations.
    Malaisse WJ
    Pharmacol Res; 1995 Sep; 32(3):111-4. PubMed ID: 8745339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Repaglinide (NN-623)].
    Kaku K
    Nihon Rinsho; 1997 Nov; 55 Suppl():180-5. PubMed ID: 9434464
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas.
    Hu S; Wang S; Dunning BE
    Int J Exp Diabetes Res; 2001; 2(1):73-9. PubMed ID: 12369729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the meglitinide analog S21403 on cationic fluxes and insulin release in perifused rat pancreatic islets exposed to a high concentration of D-glucose.
    Louchami K; Jijakli H; Malaisse WJ
    Pharmacol Res; 1999 Sep; 40(3):297-300. PubMed ID: 10479476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency.
    Juhl CB; Pørksen N; Hollingdal M; Sturis J; Pincus S; Veldhuis JD; Dejgaard A; Schmitz O
    Diabetes Care; 2000 May; 23(5):675-81. PubMed ID: 10834429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies.
    Malaisse WJ
    Eur J Clin Invest; 1999 Jun; 29 Suppl 2():21-9. PubMed ID: 10383607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia.
    Aldhahi W; Armstrong J; Bouche C; Carr RD; Moses A; Goldfine AB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4553-7. PubMed ID: 15356061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.